COMMUNIQUÉS West-GlobeNewswire
-
Basilea announces presentation of interim phase 1/2a clinical data with anticancer drug candidate BAL101553 at ASCO meeting
06/06/2017 - 07:15 -
Novartis drug Tasigna receives EU approval for inclusion of Treatment-free Remission (TFR) data in product label
06/06/2017 - 07:15 -
Targovax presents further positive clinical data from TG01 phase I/II trial at 2017 ASCO annual meeting
06/06/2017 - 07:01 -
VALNEVA Présentera à la Conférence Global Healthcare 2017 de Jefferies à New York
06/06/2017 - 07:00 -
VALNEVA to Present at Jefferies 2017 Global Healthcare Conference in New York
06/06/2017 - 07:00 -
Targovax announces formal agenda for 2017 Capital Markets Updates in Oslo and London
06/06/2017 - 07:00 -
Addex Annual General Meeting Scheduled for 22 June 2017
06/06/2017 - 07:00 -
Michael Phelps, athlète champion du monde et défenseur de la santé mentale, nommé au Conseil d'administration de Medibio
06/06/2017 - 06:34 -
Novartis announces clinical collaboration with Bristol-Myers Squibb to evaluate potential treatments in metastatic colorectal cancer
05/06/2017 - 22:05 -
NANOBIOTIX : données prometteuses de l'essai de phase I/II dans les cancers de la Tête et du Cou avec NBTXR3 ; présentées au Congres Annuel de L'ASCO
05/06/2017 - 18:00 -
NANOBIOTIX : promising data from phase I/II Head and Neck cancer trial with NBTXR3 presented at the American Society of Clinical Oncology's Annual Meeting
05/06/2017 - 18:00 -
Bio-on presents a revolutionary new technology to eliminate oil pollution in the sea within 3 weeks
05/06/2017 - 15:09 -
Bio-on présente une nouvelle technologie révolutionnaire pour éliminer en 3 semaines la pollution marine par le pétrole
05/06/2017 - 15:09 -
HalioDx : Immunosign® gene signature assesses LTX-315 ability to turn 'cold' tumors 'hot' at ASCO 2017
05/06/2017 - 15:00 -
HalioDx : HalioDx highlights use of Immunosign® to define CAR T-cell therapy signature in tumor at ASCO 2017
05/06/2017 - 15:00 -
Helsinn Group and MEI Pharma Report Correlation between Mutations in DNA Methylation Pathway and Clinical Response in Phase II Study of Pracinostat and Azacitidine in Acute Myeloid Leukemia
05/06/2017 - 15:00 -
Silmäasema Oyj's public offering has been oversubscribed and the subscription period discontinued
05/06/2017 - 15:00 -
Novartis announces ground-breaking collaboration with IBM Watson Health on outcomes-based care in advanced breast cancer
05/06/2017 - 13:15 -
Summit Presents Positive New Preclinical Data on Novel CDI Antibiotic Ridinilazole at ASM Microbe 2017
05/06/2017 - 13:00
Pages